Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PHM.MC
- Price
- 83.20
- Stock movement up
- +1.45 (1.77%)
- Company name
- Pharma Mar S.A.
- Exchange
- (MC ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.45B
- Ent value
- 1.56B
- Price/Sales
- 8.66
- Price/Book
- 7.94
- Div yield
- 0.77%
- Div growth
- -
- Growth years
- -
- FCF payout
- -64.64%
- Trailing P/E
- 2324.14
- Forward P/E
- 22.55
- PEG
- -
- EPS growth
- -
- 1 year return
- 193.58%
- 3 year return
- 2.87%
- 5 year return
- 4.50%
- 10 year return
- 5.71%
Last updated: 2025-03-29
DIVIDENDS
PHM.MC does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 2324.14 |
| Price to OCF | 876.66 |
| Price to FCF | - |
| Price to EBITDA | 1085.30 |
| EV to EBITDA | 1172.50 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.66 |
| Price to Book | 7.94 |
| EV to Sales | 9.35 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 17.38M |
| EPS (TTM) | 0.04 |
| FCF per share (TTM) | -1.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 167.00M |
| Gross profit (TTM) | 157.68M |
| Operating income (TTM) | -4.72M |
| Net income (TTM) | 622.00K |
| EPS (TTM) | 0.04 |
| EPS (1y forward) | 3.69 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 94.42% |
| Operating margin (TTM) | -2.83% |
| Profit margin (TTM) | 0.37% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.80M |
| Net receivables | 33.70M |
| Total current assets | 238.02M |
| Goodwill | 0.00 |
| Intangible assets | 1.24M |
| Property, plant and equipment | 0.00 |
| Total assets | 333.13M |
| Accounts payable | 35.20M |
| Short/Current long term debt | 38.48M |
| Total current liabilities | 89.44M |
| Total liabilities | 150.96M |
| Shareholder's equity | 182.17M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 1.65M |
| Capital expenditures (TTM) | 19.32M |
| Free cash flow (TTM) | -17.67M |
| Dividends paid (TTM) | 11.42M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 0.34% |
| Return on Assets | 0.19% |
| Return on Invested Capital | 0.32% |
| Cash Return on Invested Capital | -9.13% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 82.35 |
| Daily high | 84.90 |
| Daily low | 81.40 |
| Daily Volume | 46K |
| All-time high | 240.00 |
| 1y analyst estimate | 76.34 |
| Beta | 0.04 |
| EPS (TTM) | 0.04 |
| Dividend per share | 0.64 |
| Ex-div date | 12 Jun 2024 |
| Next earnings date | 21 Apr 2025 |
Downside potential
Loading...
Downside potential data
| PHM.MC | S&P500 | |
| Current price drop from All-time high | -65.33% | -9.34% |
| Highest price drop | -95.40% | -56.47% |
| Date of highest drop | 26 Oct 2018 | 9 Mar 2009 |
| Avg drop from high | -70.33% | -11.07% |
| Avg time to new high | 73 days | 12 days |
| Max time to new high | 6227 days | 1805 days |
COMPANY DETAILS
Marketcap
1.45B
Marketcap category
Small-cap
Description
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Employees
509
Website
Investor relations
-
SEC filings
CEO
Country
Spain
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As European markets experience a mix of modest gains and losses, with the pan-European STOXX Europe 600 Index rising slightly amid hopes for increased government spending, investors are navigating a l...
March 27, 2025
Amidst a backdrop of uncertainty surrounding U.S. trade policy and economic fluctuations, the European market has been experiencing mixed results, with the pan-European STOXX Europe 600 Index ending l...
March 14, 2025
As global markets continue to navigate the complexities of rising inflation and shifting trade policies, U.S. stock indexes have climbed toward record highs, with growth stocks leading the charge. In ...
February 21, 2025
Global markets have been experiencing fluctuations, with U.S. stocks ending the week lower amid tariff uncertainties and mixed economic indicators such as a cooling labor market and expanding manufact...
February 11, 2025
In the current volatile global market environment, characterized by fluctuating corporate earnings and geopolitical tensions, investors are increasingly on the lookout for opportunities that may be tr...
February 4, 2025
As global markets experience a rebound fueled by easing core U.S. inflation and strong bank earnings, the focus has shifted to how growth stocks are navigating these conditions. In this environment, c...
January 23, 2025
As global markets navigate a choppy start to the year, with small-cap stocks underperforming and inflation concerns persisting, investors are closely watching economic indicators and policy updates th...
January 13, 2025
As global markets navigate a mixed start to the new year, with U.S. stocks closing out a strong 2024 despite some recent volatility, investors are keenly observing economic indicators like the Chicago...
January 6, 2025
As global markets navigate the complexities of interest rate adjustments and political uncertainties, investors are closely watching how these factors impact major indices. Despite recent declines in ...
December 25, 2024
As global markets navigate a landscape marked by record highs in major indexes like the S&P 500 and Nasdaq Composite, contrasted with declines in the Russell 2000, growth stocks have notably outperfor...
December 13, 2024
Next page